• Oct 5, 2026

  $29.28-2.20%

  Viking Therapeutics closed down 2.20%, while comparable pharmaceutical preparations companies rose 1.67% on average, with 3 of 5 falling and 2 rising [1]. The move was therefore not shared by the cohort on average.

  • 1Peer group

• Oct 2, 2026

  $29.94-1.87%

  Viking Therapeutics closed down 1.87%, while comparable Pharmaceutical Preparations companies moved -0.73% on average, with 3 of 5 falling and 2 rising [1]. The company's decline was larger than the cohort's average move, so it was only partly shared [1].

  • 1Peer group

• Oct 1, 2026

  $30.51-6.41%

  Comparable Pharmaceutical Preparations companies fell 3.12% on average, with 4 of 5 declining [1]. Viking's 6.41% drop came alongside that weakness but was about twice as large as the cohort average [1].

  • 1Peer group

• Sep 30, 2026

  $32.60+2.48%

  Viking rose while comparable pharmaceutical preparations companies fell 1.31% on average, with 4 of 5 declining [2]. The move was therefore not shared by the cohort. The Motley Fool published a piece on Viking's stock and weight-loss drug data, but its headline gives no date or period for the move it describes [1].

  • 1The Motley Fool
  • 2Peer group

• Sep 29, 2026

  $31.81-3.69%

  Viking fell 3.69% while comparable pharmaceutical preparations companies moved -0.77% on average, with 3 of 5 rising [2]. The decline was larger than the cohort's and was not shared by most peers. The Motley Fool published a piece on Eli Lilly's stock barely moving after Viking's clinical results [1].

  • 1The Motley Fool
  • 2Peer group

• Sep 28, 2026

  $33.03-7.11%

  Seeking Alpha reported that Viking netted about $550M in proceeds from its latest offering [2]. Comparable Pharmaceutical Preparations companies were essentially flat, moving +0.03% on average, so the 7.11% drop was not shared by the cohort [3]. Kuehn Law also issued a notice saying it was investigating whether certain officers and directors of the company had breached duties [1].

  • 1Pr Newswire
  • 2Seeking Alpha
  • 3Peer group

• Sep 25, 2026

  $35.56-3.24%

  Viking Therapeutics shares fell 3.24% even as comparable pharmaceutical preparations companies were roughly flat, up 0.18% on average, meaning the decline was not shared by peers [1]. The session saw volume run at 2.2x the trailing average with prices ranging between 35.10 and 39.05 [2].

  • 1Peer group
  • 2Market data

Closing prices for VKTX. Summaries describe past sessions only and are not advice, a forecast or a recommendation.

Headlines are published by third parties and linked as reported. Amaltash does not endorse or verify them.